Lilly Rallies The Troops: Price Controls Would Trigger “Death Spiral”
Executive Summary
Any erosion of free pricing or intellectual property protections in the U.S. pharmaceutical market would lead to a new wave of consolidation in the industry, Lilly CEO Sidney Taurel told the American Enterprise Institute March 18 in Washington, D.C
You may also be interested in...
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
Rx Image Troubles Reflect Flaws In Health Insurance Coverage, Lilly CEO Says
A better health insurance system would help the image of the pharmaceutical industry, Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4